In this issue:
Toxicity profile of combined immune checkpoint inhibitors and thoracic RT
Bemarituzumab for FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma
EP or IP in patients with advance neuroendocrine carcinoma
FLOT vs FLOT therapy of HER2-positive resectable oesophagogastric adenocarcinoma
Alcohol consumption and risk of BTC
Lanreotide as maintenance therapy after first-line treatment
Safety and efficacy of atezolizumab plus bevacizumab for HCC
Previous cancer history on the OS of patients with gastric cancer
Safety and efficacy of atezolizumab plus bevacizumab
Ablative RT in oligometastatic pancreatic cancer
Please login below to download this issue (PDF)